Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases

行政核心摘要 行政核心支持名为“儿科和发育药理学”的项目 《炎症性传染病》作为儿科发育研究的专业中心 加州大学圣地亚哥分校药理学(RPDP)课程(U54)。行政核心的目标是使 确保整个加州大学圣地亚哥分校的RPDP计划通过 遵循目标。在目标1中，核心将促进不同群体之间的沟通和整体凝聚力 加州大学圣地亚哥分校RPDP中心的要素，以确保高效运营。为此，行政部门 CORE将专注于组织其小组会议、务虚会和日记俱乐部，并通过解决和解决 任何和所有出现的体制问题。在目标2中，核心将跟踪加州大学圣地亚哥分校的财务状况 RPDP中心，并协调IRB、FDA和NIH的报告生成。在目标3中，核心将提供 持续进行关键评估和结果评估，以实现RPDP的持续改进 通过组织对计划进行独立的外部和内部审查来实现有效性。《科学》 咨询委员会将在其成员评估RPDP中心并将他们的专业知识提供给 推动科学进步。在目标4中，核心将促进跨学科研究和 将作为寻求与RPDP合作的外部实体的联系点，包括NICHD， 其他由NICHD支持的儿科药理学培训(T32)项目、其他RPDP中心和行业。 通过AIM 5，核心将协调试点项目申请进程，并监测项目执行情况和 结果。对于目标6，行政核心将支持定量药代动力学和 药效学(PK/PD)对项目的需求进行建模，并提供及时、准确和经济高效的 通过建立一个临床项目来支持项目分析需求的定量分析 儿科领域的领军人物埃德蒙·卡帕雷利博士领导的药理科 PK/PD建模。通过AIM 7，行政核心将寻求继续保持 加州大学圣地亚哥分校RPDP通过培训和外展科培训儿科临床药剂师， 由阿德里亚纳·特雷穆雷博士领导，他是最近由NICHD资助的临床药理学T32奖的联合PI。这 培训和外展科将提供综合教育和实际指导研究培训 有志成为领导者的健康科学专业人员的儿科临床药理学经验 在战场上。这也将成为跨RPDP中心交叉培训的平台。高效 组织、管理和沟通是RPDP中心整体成功的关键，特别是在 研究的翻译性。我们作为RPDP中心在过去五年的成功证明 我们有能力有效地管理这样一个中心，并表明我们有能力推动成功的 临床和基础科学研究人员之间的互动，以促进儿科药理学领域的发展。

Administrative Core Abstract The Administrative Core supports the program entitled “Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases” as a Specialized Center in Research in Pediatric Developmental Pharmacology (RPDP) Program (U54) at UC San Diego. The goal of the Administrative Core is to make certain that the entire UC San Diego RPDP program functions as efficiently and optimally as possible via the following aims. In Aim 1, the Core will promote communication and overall cohesiveness among the various elements of the UC San Diego RPDP Center to ensure efficient operations. To that end, the Administrative Core will focus on organizing its group meetings, retreats, and journal clubs, and by addressing and solving any and all institutional issues that arise. In Aim 2, the Core will track the financial status of the UC San Diego RPDP Center and coordinate report generations for the IRB, FDA and NIH. In Aim 3 the Core will provide ongoing critical evaluation and outcomes assessment to achieve continual improvement of RPDP effectiveness by organizing independent external as well as internal reviews of the program. The Scientific Advisory Committee will serve a key role as its members evaluate the RPDP Center and lend their expertise to promote scientific progress. In Aim 4 the Core will promote the integration of cross-disciplinary research and will serve as point of contact for outside entities seeking to collaborate with the RPDP, including the NICHD, other NICHD-supported Pediatric Pharmacology Training (T32) Programs, other RPDP Centers and industry. Through Aim 5 the Core will coordinate the pilot project application process and monitor project execution and outcomes. With Aim 6 the Administrative Core will support the quantitative pharmacokinetic and pharmacodynamics (PK/PD) modeling needs of the Projects and provide timely, accurate, and cost effective quantitative assays in support of the analytical needs of the Projects through the establishment of a Clinical Pharmacology Section under the leadership of Dr. Edmund Capparelli, a leader in the field of pediatric PK/PD modeling. Through Aim 7 the Administrative Core will seek to continue the excellent track record of the UC San Diego RPDP in training pediatric clinical pharmacologists through a Training and Outreach Section, lead by Dr. Adriana Tremoulet, co-PI of a recently awarded NICHD-funded T32 in Clinical Pharmacology. This Training and Outreach Section will provide an integrated educational and practical mentored research training experience in pediatric clinical pharmacology for health sciences professionals interested in becoming leaders in the field. This will serve as the platform for cross-training across the RPDP Centers as well. Efficient organization, administration and communication is essential for overall RPDP Center success especially given the translational nature of the research. Our success over the last five years as an RPDP Center demonstrates our ability to effectively administrate such a Center and demonstrates our ability to promote the successful interactions between clinical and basic science investigators to advance the field of pediatric pharmacology.